Valerio Therapeutics
C4X
Company Profile
Business description
Valerio Therapeutics is a clinical-stage biotechnology company developing drug candidates using three proprietary platforms: the PlatON platform, DecoyTAC, and the V-Body platform, generating single-domain therapeutic antibodies. The Company is focused on bringing early-stage first-in-class or disruptive compounds from translational research to clinical proof-of-concept, a value-creating inflection point appealing to potential partners. Its pipeline includes Metabolic Diseases, Immunology & Inflammatory.
Contact
49, Boulevard du General
Martial Valin
Paris75015
FRAT: +33 145587600
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
25
Stocks News & Analysis
stocks
This onetime AI market darling is now surprisingly undervalued
This AI leader qualifies as a GARP stock today.
stocks
Undervalued ASX miner hits production homerun
Record volumes, lower costs and reduced debt underpin a stronger earnings outlook for ASX miner.
stocks
Meta earnings: AI-driven improvements in top line fail to impress investors
We reiterate our fair value estimate for wide-moat Meta and view the after-market selloff as an overreaction
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,137.00 | 70.20 | -0.76% |
| CAC 40 | 8,509.64 | 24.00 | 0.28% |
| DAX 40 | 25,629.24 | 17.21 | 0.07% |
| Dow JONES (US) | 52,452.01 | 243.95 | 0.47% |
| FTSE 100 | 10,868.05 | 29.22 | -0.27% |
| HKSE | 25,884.43 | 25.55 | 0.10% |
| NASDAQ | 25,262.31 | 140.14 | 0.56% |
| Nikkei 225 | 64,362.02 | 2,494.59 | 4.03% |
| NZX 50 Index | 13,699.28 | 63.50 | -0.46% |
| S&P 500 | 7,469.85 | 32.22 | 0.43% |
| S&P/ASX 200 | 8,976.80 | 73.10 | -0.81% |
| SSE Composite Index | 3,832.26 | 27.57 | 0.72% |